共 48 条
- [41] Phenylalanine (PHE) control in patients with phenylketonuria (PKU) consuming a novel metabolic medical food (add ins)JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 : 21 - 21Shaw, H. J.Singh, R.Yannicelli, S.
- [42] Budgetary impact of thiazolidinedione (TZD) add-on therapy relative to insulin (INS) add-on therapy in individuals treated with sulfonylureas (SU): A third party payer's perspectiveDIABETES, 2007, 56 : A653 - A653Balu, SanjeevArondekar, BhaktiLee, Won ChanHorblyuk, RuslanPashos, Chris L.
- [43] Treatment satisfaction with insulin (INS) add-on to rosiglitazone/metformin (RSG/MET) fixed-dose combination therapy (FDCT) vs. INS switch from RSG/METDIABETES, 2006, 55 : A117 - A117Horblyuk, R.Arondekar, B.Donaldson, J.Chen, H.
- [44] Insulin (INS) add-on to rosiglitazone/metformin (RSG/MET) fixed-dose combination therapy (FDCT) vs. INS switch from RSG/MET FDCT: Satisfaction with treatmentDIABETOLOGIA, 2006, 49 : 488 - 488Horblyuk, R.Arondekar, B.Donaldson, J.Chen, H.
- [45] Saxagliptin (SAXA) Add-On Therapy Improves Glycemic Control in Patients (Pts) with Poorly Controlled Type 2 Diabetes (T2D) on Insulin (INS) Alone or INS Combined with Metformin (MET)DIABETES, 2011, 60 : A304 - A304Charbonnel, BernardBarnett, Anthony H.Donovan, MarkFleming, DouglasChen, Roland
- [46] Quality Measure Outcomes with Dapagliflozin (DAPA) Add-on to Metformin (MET) or Insulin (INS) in Patients with Type 2 Diabetes (T2D)DIABETES, 2016, 65 : A307 - A307Mansfield, TraciBell, KellyRezvani, GeoffreyShatskov, AllaSheehan, John J.
- [48] Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/ INS)DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1176 - 1185Terauchi, YasuoTamura, MasahiroSenda, MasayukiGunji, RyojiKaku, Kohei